Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

The addition of obinutuzumab to standard care increased the complete renal response rate by 13.4 percentage points in patients with active proliferative lupus nephritis. Obinutuzumab, an anti-CD20 ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, reinforcing its potential as an effective treatment option while also allowing ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Conventional lupus nephritis (LN) treatment based on cyclophosphamide ... [1] It usually arises within 5–10 years of diagnosis and its prevalence varies depending on the population and the ...

ALMS was a well-designed, randomized, controlled trial that included 370 patients with systemic lupus erythematosus (SLE) and class III, IV, or V nephritis. Like every recent major trial of new ...

The Phase 1 GALLOP study evaluating investigational therapy, CB-010, for treatment of lupus nephritis (LN) has officially started ... which is defined as lupus that is not characterized by Class ...

No writing assistance was utilized in the production of this manuscript. Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus. Immunological features ...